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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To compare the effects of six-month versus longer regimens for abdominal tuberculosis (TB), consisting of a two-month intensive
phase with rifampicin, isoniazid, pyrazinamide, and ethambutol followed by a four-month or longer continuation phase including at
least isoniazid and rifampicin.
B A C K G R O U N D
Description of the condition
Tuberculosis (TB) is an infectious disease caused by infection with
bacterial species of the Mycobacterium tuberculosis (M. tuberculo-
sis) complex. The World Health Organization (WHO) has es-
timated that 9.6 million people developed the disease in 2014
(WHO 2015). Alongside human immunodeficiency virus (HIV),
TB remains a leading cause of death worldwide and caused 1.5
million deaths in 2014, mostly in low- and middle-income coun-
tries (WHO 2015). There is also increasing incidence of TB in
developed countries due to HIV co-infection, the increased use of
immunosuppressive therapy, and migration from high TB burden
countries (Debi 2014; Kim 2003).
TB affects mainly the lungs (pulmonary TB), but can spread to
other organs (extrapulmonary TB, EPTB). The term abdominal
TB refers to TB infection in any of the structures within the ab-
dominal cavity, which includes the gastrointestinal tract, the peri-
toneum (the lining of the abdominal cavity), the lymph nodes
within the abdomen, and any of the solid organs in the abdomen
(liver, pancreas, spleen). Appendix 1 outlines the various forms of
abdominal TB. Abdominal TB can present as isolated involvement
of the gastrointestinal tract, the peritoneum, lymph nodes, or solid
viscera, or as involvement of multiple sites (Debi 2014). The most
common forms of abdominal TB affect the gastrointestinal tract
with the ileocaecal area being the most common site involved, and
the peritoneum (Bolukbas 2005). In children, adhesive peritoni-
tis and lymphadenopathy are the commonest forms of abdominal
TB (Tinsa 2010). Routine data collection by most national TB
programmes worldwide does not currently report EPTB cases by
organ system affected and estimates of prevalence vary consider-
ably for abdominal TB, ranging from 3% to 17% of EPTB cases
(Khan 2006; Sharma 2004; Sheer 2003). Some data reported ab-
dominal TB as the sixth most frequent site of EPTB (Sheer 2003).
Although abdominal TB can be detected in individuals of any
1Six months therapy for abdominal tuberculosis (Protocol)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
age, young adults between 25 and 45 years are most commonly
affected (Lazarus 2007). Abdominal TB can result from swallow-
ing infected sputum, ingestion of contaminated milk products or
meat, haematogenous spread from tubercular focus in any other
organ, spread via lymphatics from infected nodes, and contiguous
spread from adjacent organs (Debi 2014; Lazarus 2007). The clin-
ical presentation depends on the site infected. Abdominal pain,
abdominal distension, diarrhoea, and constitutional symptoms of
TB, such as weight loss and fever, are frequent manifestations of
intestinal TB (Bolukbas 2005; Mamo 2013). The onset is insid-
ious in most cases, but intestinal TB may present acutely with
complications, such as intestinal obstruction and perforation. In
addition to the common manifestations of abdominal TB, other
symptoms may be present depending on the infected site. Colonic
TB may present with chronic diarrhoea or recurrent partial in-
testinal obstruction and, uncommonly, with bleeding from the
gastrointestinal tract, and rectal lesions such as anal fissures, fistu-
lae, or perirectal abscesses (Golden 2005). Tuberculous peritonitis
commonly presents with ascites (Debi 2014).
Microbiological diagnosis of abdominal TB by culture of the
organism is difficult, and the diagnosis is usually based on
histopathological and radiological findings (Debi 2014; Mamo
2013). Barium contrast and abdominal computerized tomogra-
phy with enterography (CT-E) are helpful in establishing the di-
agnosis of gastrointestinal TB. Biopsy of the area affected in the
gastrointestinal tract can be obtained by endoscopy or even laparo-
tomy, in order to increase chances of definite diagnosis by identi-
fication of M. tuberculosis. Regarding TB peritonitis, examination
of ascitic fluid usually shows characteristics of exudate, with high
protein content, lymphocytic predominance, and high adenosine
deaminase levels. Culture of peritoneal (ascitic) fluid has very low
sensitivity for isolation of M. tuberculosis, although concentration
methods such as centrifugation may improve the yield. Culture
of peritoneal biopsy specimens has a higher sensitivity. Peritoneal
specimens can be obtained with ultrasound guidance or via la-
paroscopy/laparotomy (Golden 2005).
Abdominal TB is considered a great mimicker of other diseases
involving the abdomen. Regarding intestinal TB, the differential
diagnosis includes Crohn’s disease, cancers, and other infectious
diseases such as amoebiasis, gastrointestinal histoplasmosis, and
Yersinia enterocolitis (Bolukbas 2005). Therefore, a high index
of suspicion is required to make a prompt diagnosis and to start
antituberculous therapy, which is essential to limit complications
and prevent death (Balasubramanian 1997; Lazarus 2007).
Description of the intervention
Standardized international recommendations for treating people
with pulmonary TB consist of six-month antituberculous regi-
mens, including isoniazid (H), rifampicin (R), and pyrazinamide
(Z), usually with ethambutol (E) as a fourth drug during the first
two months of treatment (intensive phase), followed by isoniazid
and rifampicin for four additional months (continuation phase)
(WHO 2010). In a person suffering from TB, M. tuberculosis is
present in replicating and slow- or non-replicating states. Bacilli
in slow- or non-replicating states are tolerant to some antitubercu-
lous drugs, and it is believed that these are responsible for the need
for long antituberculous regimens with a combination of drugs
(Raffetseder 2014; Zumla 2014). The discovery of new antitu-
berculous drugs over the last decades, along with trials assessing
different combinations and doses of antituberculous drugs, has
allowed shortening of treatment duration for pulmonary TB to
six months, also known as short-course antituberculous therapy
(Menzies 2009; Zumla 2014). The basic principles of antituber-
culous treatment for pulmonary TB have been extrapolated to the
extrapulmonary TB forms, with exceptions such as TBmeningitis.
Most current guidelines recommend the same six-month regimen
for pulmonary TB for treating people with drug-sensitive abdomi-
nal TB (American Thoracic Society 2003;WHO2010).However,
these recommendations have not been supported by high quality
evidence. EPTB cases were excluded from trials that evaluated the
effectiveness of six-month antituberculous therapy, because of dif-
ficulties in establishing a microbiological diagnosis and the lack
of clear and reliable parameters for assessing treatment outcome
(Kim 2003). There is reluctance among physicians, especially in
developing countries, to treat abdominal TB with six-month reg-
imens. This is based on concerns that short-course antitubercu-
lous treatment may not be long enough to eliminate slow- or non-
replicating bacilli in the infected site in order to prevent relapse of
the disease, and because of the difficulties in assessing treatment
response in abdominal TB (Park 2009). Thus, despite the current
recommendations, many clinicians still treat patients with abdom-
inal TB for more than six months (Debi 2014; Makharia 2015).
How the intervention might work
Some trials have reported that six-month antituberculous regi-
mens are as effective as longer regimens in treatment of abdominal
TB (Balasubramanian 1997; Makharia 2015). Long treatments
are associated with poor adherence and loss of participants to fol-
low-up, which leads to increased relapse rates and mortality. Poor
patient compliance also facilitates the development of drug-resis-
tant TB strains when programmatic conditions are not optimal
(Zumla 2014). Finally, the other disadvantages of longer regimens
are increased cost, and increased exposure to antituberculous drugs
which may lead to increased drug toxicity (Park 2009).
On the other hand, relapse of the disease remains a concern when
treating people with abdominal TB for six months. Short-course
regimens may not be long enough to eliminate slow- or low-repli-
cating mycobacteria in the infected sites, leading to higher relapse
rates. Somemanifestations of abdominal TBmay affect absorption
of the drugs, which could lead to specific concerns about whether
the concentration of the drugs is sufficient at the site of infection
in such patients.
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According to the literature on pulmonary TB, most relapses occur
within the first six to 12 months after completion of antituber-
culous treatment (American Thoracic Society 2003; Park 2009).
By extrapolating basic principles of pulmonary TB treatment to
EPTB treatment due to a lack of data for abdominal TB treatment,
a minimum of six months follow-up after treatment completion
is required to assess the relapse outcome. TB infection can relapse
many years after initial treatment, so ideally long follow-up periods
are required to assess relapse rates. However, most deaths associ-
ated with abdominal TB seem to occur within the first weeks after
diagnosis (Mamo 2013). Deaths are reduced by prompt diagnosis
and early initiation of antituberculous therapy (Debi 2014), and
the role of duration of antituberculous therapy in reducing deaths
is uncertain.
Why it is important to do this review
The key concern for acceptance of a six-month regimen for ab-
dominal TB is whether six-month regimens achieve successful
treatment rates that are as good as longer regimens without signif-
icantly increasing the number of relapses. Few trials have assessed
the effectiveness of six-month regimens versus longer regimens for
this form of TB (Makharia 2015; Park 2009; Tony 2008). As re-
lapse is a relatively uncommon event, large numbers of partici-
pants are required to assess this outcome, and existing trials may
be underpowered to detect a difference in relapse rates. Therefore,
a meta-analysis may be helpful to estimate the effect of six-month
antituberculous therapy on relapse rates in people with abdominal
TB.
Two review authors (SJu and HR) conducted an evidence review
to compare the effects of treatment with the six-month first-line
regimen 2RHZE/4RH versus the nine-month regimen 2RHZE/
7RH for abdominal TB for the Indian Extra-Pulmonary TB (IN-
DEX-TB) guidelines, which forms the preliminary work for this
Cochrane Review (INDEX-TB 2016).
O B J E C T I V E S
To compare the effects of six-month versus longer regimens for
abdominal tuberculosis (TB), consisting of a two-month intensive
phase with rifampicin, isoniazid, pyrazinamide, and ethambutol
followed by a four-month or longer continuation phase including
at least isoniazid and rifampicin.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs) or quasi-RCTs.
Types of participants
Adults and children with a diagnosis of presumed drug-sensitive
abdominal TB as defined by the trial authors, from all settings and
countries.
Types of interventions
Short-course regimens
Six-month antituberculous regimens that contain a two-month
intensive phase with rifampicin, isoniazid, pyrazinamide, and
ethambutol, followed by a continuation phase of four months that
includes at least isoniazid and rifampicin.
Prolonged-course regimens
Antituberculous regimens of more than six months that contain
a two-month intensive phase with rifampicin, isoniazid, pyrazi-
namide, and ethambutol, followed by a continuation phase that
includes at least isoniazid and rifampicin.
Types of outcome measures
Primary outcomes
• Relapse: participants who have new symptoms and signs of
abdominal TB after resolution of disease and completion of
antituberculous treatment.
• Clinical cure: participants who completed treatment
according to the original treatment plan without evidence of
treatment failure at the end of treatment (WHO 2013).1
1TheWHO’s definitions for TB outcomes are primarily based on
the assessment of pulmonary TB patients, so sputum smear and
culture status are important factors in defining outcomes. Gener-
ally, repeating biopsy of the infected tissue for histopathology and
culture at the end of antituberculous therapy is not done routinely
in patients with abdominal TB. Therefore, in practice, bacteri-
ological status is not part of the definition of cure or successful
treatment. We anticipate that trial authors may define cure and
treatment failure in different ways, including symptomatic cure
and resolution of lesions on radiological imaging or endoscopy.
Wewill specify the definition of clinical cure used in each included
trial and collect outcome data accordingly.
Secondary outcomes
• Death from any cause.
• Treatment failure: failure to improve with antituberculous
treatment, or deterioration following initial improvement while
on antituberculous treatment.
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• Default: participants who discontinue antituberculous
treatment before the end of treatment, or participants whose
treatment is interrupted for eight weeks or more consecutively
(WHO 2013).
• Poor adherence: lack of compliance with the treatment
regimen, as reported by the trial authors, but does not meet the
definition of ‘default’ outlined above.
• Complete healing of active lesions, documented by
endoscopy or histopathology.
Adverse events
• Serious adverse events that are life-threatening or lead to
hospitalization.
• Adverse events that lead to the discontinuation of
antituberculous treatment.
• Other adverse events relating to antituberculous treatment.
Timing of outcome assessment
For RCTs that report on relapse, we will include those with a
minimumof sixmonths follow-up after antituberculous treatment
completion.
Search methods for identification of studies
Wewill attempt to identify all relevant trials regardless of language
or publication status (published, unpublished, in press, and on-
going).
Electronic searches
We will search the following electronic databases, using the
search terms and strategy described in Appendix 2: PubMed
(including MEDLINE), EMBASE (accessed via OvidSP), the
Cochrane InfectiousDiseasesGroup (CIDG) SpecializedRegister,
the Cochrane Central Register of Controlled Trials (CENTRAL),
LILACS, INDMED, and the South Asian Database of Controlled
Clinical Trials. We will search ClinicalTrials.gov and the search
portal of theWHO International Clinical Trials Registry Platform
(www.who.int/trialsearch) to identify ongoing trials.
Searching other resources
We will check the reference lists of existing reviews and of all trials
identified by the above methods that meet our eligibility criteria,
for other potentially relevant trials.
Data collection and analysis
Selection of studies
Two review authors (SJu and SJa) will each independently screen
the titles and abstracts of the studies identified by the literature
search for studies thatmaymeet eligibility criteria, andwill remove
duplicate reports. We will retrieve the full-text articles of poten-
tially eligible studies. SJu and SJa will then independently assess
the full-text studies for study eligibility using an eligibility form
that is based on the predefined inclusion and exclusion criteria.
We will resolve any disagreements by discussion, and will involve
a third review author if necessary. Where eligibility is unclear we
will attempt to contact the trial authors for clarification. We will
list excluded studies together with the reasons for exclusion.
Data extraction and management
One review author (SJu) will pilot the data extraction form on two
included trials. Based on the pilot results, we may modify the data
extraction form and we will finalize it. Two review authors (SJu
and SJa) will then independently extract data from the included
trials according to the agreed data extraction tool.Wewill compare
the data extracted by the two review authors to identify possible
errors. We will resolve any discrepancies through discussion and
by referring to the original articles. We will extract the following
data.
• Country, setting, when the trial was conducted, study
design, inclusion and exclusion criteria applied, number of
participants recruited to each trial arm.
• Participant characteristics: age, gender, epidemiological data
such as known contact with TB patient, duration of the disease
at presentation, severity of disease at presentation (as reported by
the trial authors), features of malabsorption, site of the disease,
comorbidity (HIV, malnutrition, other immunosuppressive
conditions, and other diseases), co-existing pulmonary TB or
concurrent TB infection in any other organ, diagnostic methods
and results (PPD skin test in mm, microscopy, culture, histology
and cytology of ascitic fluid, lymph node aspirate or biopsy,
other tissue biopsy, chest X-ray, abdominal X-ray, barium enema,
CT of the abdomen, endoscopy, laparoscopy, surgery), number
of bacteriologically confirmed and clinically diagnosed cases of
abdominal TB, and history of previous antituberculous therapy
received.
• Intervention data: antituberculous drugs, dose, route of
administration in both the intensive and continuation phases,
and duration of each phase. Administration of other drugs or
therapeutic procedures. Administration of treatment under
directly observed short-course therapy (DOTs) or unsupervised/
home treatment.
• Outcome data: for relapse, we will extract data on relapse
rate, clinical severity of relapse, method of diagnosis, and time
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between end of treatment and relapse. For clinical cure, we will
extract the exact definition used by the trial authors. For
assessing defaulters and adherence, we will examine the methods
for assuring adherence, including clinical history, direct
observation, and tablet counting. We will extract data on the
number of defaulters, and the number of participants with poor
compliance, based on the definitions stated in the ’Secondary
outcomes’ section. For all the outcomes, we will extract, if
available, data on site of disease and on HIV status.
• Follow-up: length of follow-up, the way participants were
followed up, the number and characteristics of losses to follow-
up.
For each established outcome, we will extract the number of par-
ticipants randomized and the number of participants analysed in
each treatment group. For dichotomous outcomes, we will extract
the number of participants that experience the event. For count
data outcomes, we will extract the number of events in the inter-
vention and control group, the rate ratio, and the standard error.
Assessment of risk of bias in included studies
Two review authors (SJu and SJa) will independently assess the
methodological quality of each included trial using the Cochrane
’Risk of bias’ assessment tool, which addresses sequence genera-
tion, allocation concealment, blinding of participants and person-
nel, blinding of outcome assessment, incomplete outcome data,
selective outcome reporting, and other biases (Higgins 2011). For
each component, we will classify our judgments as either ’low’,
’high’, or ’unclear’ risk of bias. We will resolve any discrepancies
through discussion between the two review authors or we will
contact a third review author if required. We will summarize the
results of the assessment in ’Risk of bias’ graphs and ’Risk of bias’
tables, with supporting evidence from the trial reports.
Measures of treatment effect
We will calculate the risk ratio (RR) for dichotomous outcomes.
We will use the rate ratio for count data outcomes. We will present
the effect estimates with 95% confidence intervals (CIs). If the RR
value is inappropriate to evaluate the effect estimate of uncommon
events, we will use the risk difference.
Dealing with missing data
It is possible to impute data using best and worst-case scenario
analyses (that is, the ‘best-case’ scenario is that all participants
with missing outcomes in the experimental intervention group
had good outcomes, and all those with missing outcomes in the
control intervention group had poor outcomes; the ‘worst-case’
scenario is the converse). However this is an extreme adjustment,
especially where outcomes are rare, as it would be very unlikely
that all participants with missing data experienced an event for
either treatment arm. Instead, we will perform imputations using
the event rates observed in the available data. As an available case
analysis implicitly assumes that the event rates observed also apply
to the missing data, we will vary the observed event rates within
reasonable limits, and apply these varied event rates to the missing
data, so that the resulting sensitivity analyses represent plausible
scenarios that may have occurred within the missing data. This
will allow us to investigate how plausible missing data scenarios
would impact the overall effect estimate.
Assessment of heterogeneity
We will assess clinical and methodological diversities by looking
at the variability in participants, interventions, outcomes, study
design, and risk of bias in the included trials. If possible, we will
assess statistical heterogeneity by inspecting the forest plots for
overlapping CIs, by applying the Chi² test with a P value of 0.10
used to indicate statistical significance, and by using the I² statistic
with a value of 50% used to denote a moderate level of hetero-
geneity.
Assessment of reporting biases
If we include 10 or more trials, we will construct a funnel plot to
assess publication bias.
Data synthesis
We will summarize all included trials in the ’Characteristics of in-
cluded studies’ tables. If data are available, we will group the in-
cluded trials by site of disease: gastrointestinal tract, peritoneum,
lymph nodes, and solid viscera. We will analyse the data with Re-
view Manager (RevMan) (RevMan 2014). We will solicit guid-
ance from a statistician of the Cochrane Infectious Diseases Group
(CIDG) if required. To describe the effect of estimates, we will
use RR and risk difference values when appropriate as a summary
statistic for dichotomous data, with 95% CIs. We will conduct
meta-analyses if appropriate, and will use a fixed-effect model in
the first instance. If we detect moderate heterogeneity, we will use
a random-effects model. If meta-analysis is inappropriate, we will
present the data in text and tables using narrative summaries. We
will assess the quality of the evidence using the Grading of Recom-
mendations Assessment, Development and Evaluation (GRADE)
principles (Guyatt 2011). We will construct ’Summary of find-
ings’ table(s) using the GRADEpro Guideline Development Tool
(available from www.gradepro.org).
Subgroup analysis and investigation of heterogeneity
Death from abdominal TB can be related to mycobacterial bur-
den and dissemination of infection, malabsorption, malnutrition,
co-morbidities, and complications of the disease and treatment.
Death in the first six months of treatment may not be related to
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the total length of treatment, while death after six months of anti-
tuberculous therapymay be related to cessation of antituberculous
treatment in participants treated for six months. Therefore we will
explore heterogeneity by conducting subgroup analysis between
death in the first six months and after six months of antitubercu-
lous treatment.
We anticipate that we will not obtain enough data to conduct
further subgroup analyses. However, we may stratify results to
describe differences between regimens that are longer than six
months, participants who are HIV-positive or HIV-negative, and
participants treated with intermittent and daily antituberculous
treatment.
Sensitivity analysis
If there is a sufficient number of included trials, we will perform
sensitivity analyses by limiting inclusion in the meta-analysis as
follows, and we will compare the results to the primary meta-
analysis.
• Trials at low risk of bias.
• Trials with little or no missing data.
• Any individual peculiarities we identify during the review
process.
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Appendix 1. Forms of abdominal TB
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Form Anatomical site
Abdominal lymph node TB (abdominal TB lymphadenitis) Lymph nodes (mesenteric, omental, at porta hepatis, at coeliac axis)
Peritoneal TB (TB peritonitis) Peritoneum
Gastrointestinal TB Ileocaecal area (ileocolonic TB) involving the ileum and caecum
Jejunum
Colon
Oesophagus, stomach, duodenum
Visceral TB Liver, spleen, pancreas
Appendix 2. Detailed search strategies
Search set MEDLINE EMBASE
1 tuberculosis [MeSH] Tuberculosis [Emtree]
2 tuberculosis [ti, ab ] Tuberculosis [ti, ab]
3 1 or 2 1 or 2
4 Abdominal OR gastroenteric OR gastrointestinal OR in-
testinal OR enterocolitis OR peritonitis OR peritoneal OR
hepatic OR liver OR splenic [ti, ab]
Abdominal OR gastroenteric OR gastrointestinal OR in-
testinal OR enterocolitis OR peritonitis OR peritoneal OR
hepatic OR liver OR splenic [ti, ab]
5 3 and 4 3 and 4
6 “Peritonitis, tuberculous” [Mesh] “Abdominal tuberculosis”[Emtree]
7 “Tuberculosis, Gastrointestinal”[Mesh] 5 or 6
8 “Tuberculosis, Hepatic”[Mesh] 5 or 7
9 “Tuberculosis, Splenic”[Mesh] -
10 6 or 7 or 8 or 9 -
11 5 or 10 -
We will use these search terms in combination with the search strategy for retrieving trials developed by Cochrane (Lefebvre 2011).
This is the preliminary search strategy for MEDLINE and EMBASE, which we will adapt for other electronic databases. We will report
all search strategies in full in the final version of the review.
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